Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indoximod - Lumos Pharma

Next Previous
Drug Profile

Indoximod - Lumos Pharma

Alternative Names: 1 MT; 1-methyl-D-tryptophan; 1-methyltryptophan; d-1-methyltryptophan; D-1MT; NLG-8189; NSC-721782

Latest Information Update: 31 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer Augusta University; Lumos Pharma; National Cancer Institute (USA); University of Minnesota
  • Class Amino acids; Antineoplastics; Indoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Malignant melanoma
  • Phase II HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Phase I/II Glioma; Solid tumours
  • Phase I Brain cancer
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 14 Apr 2023 Pharmacodynamics data from phase I/II study in Cancer presented at the Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 08 Feb 2022 Phase-I clinical trials in Brain cancer (Combination therapy, In children, In adolescents, In adults, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT05106296)
  • 03 Nov 2021 Augusta University plans phase Ib trial for Brain cancer (Combination therapy, In children, In adolescents, In adults, Second line therapy or greater, Metastatic disease) in USA (PO) in February 2022 (NCT05106296)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top